Single Agent Pembrolizomab and Mabidotin for Metastatic Bladder Cancer

This chapter discusses the potential use of single agent pembrolizomab and mabidotin as treatments for metastatic bladder cancer, highlighting their efficacy and adverse event profile.

Transcript

Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!

Get the app